SAMUEL ROSS: Open Payments
NPI 1689917486 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 31 payments from 11 companies in 2025. Trend: 2023 $809 · 2024 $647 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $256 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Novo Nordisk Inc | 3 | $74 |
| Novartis Pharmaceuticals Corporation | 3 | $56 |
| PFIZER INC. | 2 | $54 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| ABBVIE INC. | 2 | $42 |
| Gilead Sciences, Inc. | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| Lilly USA, LLC | 1 | $30 |
Products named: GEMTESA, AIRSUPRA, LEQVIO, NURTEC ODT, CONTRAVE, Wegovy, BREZTRI, VRAYLAR.
Industry payments across CA — which companies pay providers there.
